Karolinska Development AB (publ) (KDEV.ST)

1.5180 -0.0320 (-2.06%) At close: 05:24PM CEST

Karolinska Development AB (publ)

Nanna Svartz väg 6A
Solna 17165
Sweden
46 8 52 48 60 70
https://www.karolinskadevelopment.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 8

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Viktor Drvota M.D., Ph.D.	Chief Executive Officer	4.73M	N/A	1965
Mr. Hans Christopher Toll	Chief Financial Officer	N/A	N/A	1968
Mr. Per Aniansson	Investment Director	N/A	N/A	1966
Ms. Eva Montgomerie	Head of Accounting	N/A	N/A	1958
Dr. John Öhd M.D., Ph.D.	Chief Scientific Officer & Venture Partner	N/A	N/A	1971
Mr. Johan Dighed	Chief Legal Officer & Deputy CEO	N/A	N/A	1973
Mr. Yan Cheng	President of Asia	N/A	N/A	1985
Prof. Hans Wigzell M.D., Ph.D.	Senior Strategic Advisor	500k	N/A	1938
Mr. Tse Ping	Senior Strategic Advisor	N/A	N/A	1952
Ms. Linda Spahiu	Investment Manager	N/A	N/A	1985

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

Karolinska Development AB (publ) is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. It seeks to invest in pharmaceutical research and development, medical research, healthcare technology, gene research and development, drug delivery technologies, biotechnology, and life science tools and service sectors. The firm seeks to invest in the Nordic region with a focus on Sweden, Iceland, Norway, Finland, and Denmark. It prefers to be a lead investor in its portfolio companies however does consider co-investments also. It seeks to invest in up to five projects annually. Karolinska Development AB (publ) was founded in 2003 and is headquartered in Stockholm, Sweden.

Corporate governance

Karolinska Development AB (publ)’s ISS governance QualityScore as of 1 April 2024 is 4. The pillar scores are Audit: 9; Board: 5; Shareholder rights: 7; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.